Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	6.97B +45.0%
Revenue (ttm)	1.83B +18.6%
Net Income	110.43M +11.0%
EPS	0.29 +8.1%
Shares Out	339.93M
PE Ratio	71.09
Forward PE	n/a
Dividend	0.11 (0.54%)
Ex-Dividend Date	Jul 9, 2026

Volume	19,088,123
Open	21.49
Previous Close	21.35
Day's Range	20.48 - 21.49
52-Week Range	13.55 - 50.28
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin ca, atorvastatin ca, pregabalin, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous, gastrointestinal and digestive tracts, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,370
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error